Inhibiting the Expression of Cyclin D1 Protein to Reduce the HBVDNA Level in CHB patients
DOI:
https://doi.org/10.61173/wxjwx865Keywords:
TCM, HBV, CHB, ursolic acid, Cyclin D protein,, ERK signaling pathwayAbstract
HBV virus is now affecting over 400 million people worldwide. Chronic Hepatitis B (CHB) is one of the significant clinical symptoms of HBV infection. Previous studies have reported that antiviral therapy is a practical method for patients. However, the current treatment has reached a bottleneck due to economic burden and drug resistance. As a practical component in ligustrum lucidum, ursolic acid has been found to have an antiviral effect. This study focuses on one particular mechanism of its effect. It tests its function in reducing the expression of Cyclin D1 protein to provide a possible reason for its ability to inhibit cell proliferation.
References
[1] M. Li et al., “Beneficial therapeutic effect of Chinese herbal Dean&Francis Bushen formula on CHB patients with mildly elevated alanine aminotransferase by down-regulating CD4+CD25+T cells,” J. Ethnopharmacol., vol. 146, no. 2, pp. 614–622, Mar. 2013, doi: 10.1016/j.jep.2013.01.038.
[2] C. Sun, X. Wu, and Z. Zhao, “Correlation between DNA load alanine aminotransferase and body immune function in patients with chronic hepatitis B virus infection,” Journal of Practical Medical Techniques, vol. 29, no. 03. pp. 241–244, 2022.
[3] Y. Jiang, “Research progress on the necessity of antiviral treatment for chronic hepatitis B virus carriers,” Chin. Community Dr., vol. 36, no. 06, pp. 6–7, 2020.
[4] C.-J. Chen et al., “Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level,” JAMA, vol. 295, no. 1, pp. 65–73, Jan. 2006, doi: 10.1001/ jama.295.1.65.
[5] C. Liu et al., “The relationship between serum hepatitis B virus DNA level and liver histology in patients with chronic HBV infection,” PLOS ONE, vol. 13, no. 11, p. e0206060, Nov. 2018, doi: 10.1371/journal.pone.0206060.
[6] W. Qi QI Ge, “Applied research on the progress of treatment of chronic hepatitis B virus infection,” Infect. Int. Ed., vol. 9, no. 02, pp. 337–338, 2020.
[7] L. Zhang, G. Wang, W. Hou, P. Li, A. Dulin, and H. L. Bonkovsky, “Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review,” Hepatol. Baltim. Md, vol. 51, no. 2, pp. 690–698, Feb. 2010, doi: 10.1002/hep.23384.
[8] “Liqustri lucidi Fructus inhibits hepatic injury and functions as an antioxidant by activation of AMP-activated protein kinase in vivo and in vitro - PubMed.” https://pubmed.ncbi.nlm.nih. gov/27916511/ (accessed Mar. 27, 2022).
[9] F. Si, J. Li, C. Zeng, F. Si, and X. Zhou, “Advances in antitumor activity and mechanism of action of ursolic acid,” Chem. Bioeng., vol. 27, no. 01, pp. 9–12, 2010.
[10] Z. Zhu, F. Xiang, Y. Fan, X. Kang, and R. Wu, “Research progress on the mechanism of tumor growth inhibition by ursolic acid,” Shaanxi J. Tradit. Chin. Med., vol. 41, no. 07, pp. 999–1002, 2020.
[11] D. Lei, Y. Li, and J. Qi, “Effect of ursolic acid on HepG2 proliferation and apoptosis and partial mechanism study,” Chin. J. Curr. Adv. Gen. Surg., vol. 20, no. 04, pp. 259–263, 2017.
[12] L.-Q. Li et al., “Lignans from the heartwood of Streblus asper and their inhibiting activities to hepatitis B virus.,” Fitoterapia, vol. 83, no. 2, pp. 303–309, Mar. 2012, doi: 10.1016/j.fitote.2011.11.008.
[13] Y. Zhang and J. Lin, “Analysis of the relationship between HBsAg and serological indicators in chronic hepatitis B and the establishment of HBsAg-deficient hepatitis B mouse model,” Master, Nanjing Medical University, 2017.
[14] T. Wang, H. Song, and D. Zhao, “Experimental study on the antitumor effect of ursolic acid,” Master, China Agricultural University, 2005.
[15] B. Qiao et al., “Study on the inhibitory effect of betulinic acid on HBV DNA in mice with acute plasmid infection model,” China J. Chin. Mater. Medica, vol. 39, no. 06, pp. 1097–1100, 2014.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
